Basement membrane components in lymphoid follicles: immunohistochemical demonstration and relationship to the follicular dendritic cell network.

We analyzed the distribution of two basement membrane components, laminin and type IV collagen, in human reactive and neoplastic lymphoid follicles by using immunoenzymatic and immunofluorescence methods on serial frozen sections from 11 reactive lymph nodes, three palatine tonsils, and 11 immunophenotypically defined B cell non-Hodgkin's lymphomas. The patterns of distribution of these two antigens were compared with that of follicular dendritic reticulum cells (DRCs) as visualized by anti-DRC-1 and anti-desmoplakin 1 and 2 antibodies. Immunostaining for laminin and type IV collagen produced overlapping results. Germinal centers contained some vascular and fiber-like linear staining, but the most striking feature was the presence of a large amount of punctate-granular staining. This staining was present throughout the entire area of most of the germinal centers, although often more densely in the central areas. The stronger punctate-granular staining for laminin, type IV collagen, and desmoplakin 1 and 2 corresponded to the more densely stained areas for DRC-1. Double immunofluorescence assay demonstrated that there was a close similarity between the punctate-granular staining pattern of laminin and the dendritic network of DRC-1-positive cells. In the nine B cell lymphomas of follicular center origin in which DRCs were present, although distributed in different patterns, immunostaining for laminin and type IV collagen could be observed only in those areas showing immunoreactivity for DRC-1. The results of this study suggest that the punctate-granular staining pattern for laminin and type IV collagen is specific for the follicle. This finding may be strictly related to the follicular microenvironment because the pattern of distribution displayed by laminin and type IV collagen seems to be spatially related to the staining pattern of DRCs, as visualized by the anti-DRC-1 and desmoplakins antibodies, both in reactive and neoplastic conditions.